Sales Reports. Company shall report to Hospital the date of the First Commercial Sale in each country of the License Territory within [* * *] days of each such occurrence. Following the First Commercial Sale, Company shall deliver reports to Hospital within [* * *] days after the end of each Reporting Period. Each report under this Section 5.4 shall have substantially the format outlined in Appendix C, shall be certified as correct by an officer of Company and shall contain at least the following information as may be pertinent to a royalty accounting hereunder for the immediately preceding Reporting Period: (a) the number of Products and Processes Sold by Company, its Affiliates and Sublicensees in each country; (b) the amounts billed, invoiced and received by Company, its Affiliates and Sublicensees for each Product and Process, in each country, and total ▇▇▇▇▇▇▇▇ or payments due or made for all Products and Processes; (c) calculation of Net Sales for the applicable Reporting Period in each country, including an itemized listing of permitted offsets and deductions; (d) total royalties payable on Net Sales in U.S. dollars, together with the exchange rates used for conversion; and (e) any other payments due to Hospital under this Agreement. If no amounts are due to Hospital for any Reporting Period, the report shall so state.
Appears in 3 contracts
Sources: Exclusive Patent License Agreement (Biohaven Pharmaceutical Holding Co Ltd.), Exclusive Patent License Agreement (Biohaven Pharmaceutical Holding Co Ltd.), Exclusive Patent License Agreement (Biohaven Pharmaceutical Holding Co Ltd.)
Sales Reports. Company shall report to Hospital the date of on which it achieves the First Commercial Sale in each country of the License Territory within [* * ***] days of after each such occurrence. Following the First Commercial Sale, Company shall deliver reports to Hospital within [* * ***] days after the end of each Reporting Period. Each report under this Section 5.4 5.3 shall have substantially the format outlined in Appendix CB, shall be certified as correct by an officer of Company and shall contain at least the following information as may be pertinent to a royalty accounting hereunder for the immediately preceding Reporting Period:
(a) the number of Products and Processes Sold by Company, its Affiliates and Sublicensees in each country;
(b) the amounts billed, invoiced and received by Company, its Affiliates and Sublicensees for each Product and Process, in each country, and total ▇▇▇▇▇▇▇▇ or payments due or made for all Products and Processes;
(c) calculation of Net Sales for the applicable Reporting Period in each country, including including, to the extent reasonably possible, an itemized listing of permitted offsets and deductions;
(d) total royalties payable on Net Sales in U.S. dollars, together with the exchange rates used for conversion; and
(e) and any other payments due to Hospital under this Agreement. If no amounts are due to Hospital for any Reporting Period, the report shall so state.
Appears in 2 contracts
Sources: Exclusive Patent License Agreement (Seer, Inc.), Exclusive Patent License Agreement (Seer, Inc.)
Sales Reports. Company shall report to Hospital the date of on which it achieves the First Commercial Sale in each country of the License Territory within [* * ***] days of each such occurrence. Following the First Commercial Sale, Company shall deliver reports to Hospital within [* * ***] days after the end of each Reporting Period. Each report under this Section 5.4 5.3 shall have substantially the format outlined in Appendix CB, shall be certified as correct by an officer of Company and shall contain at least the following information (or as otherwise determined by the Steering Committee) as may be pertinent to a royalty accounting hereunder for the immediately preceding Reporting Period:
(a) the number of Products and Processes Sold by Company, its Affiliates and Sublicensees in each countryof (i) the United States, (ii) the European Union, (iii) Japan and (iv) all other countries in aggregate (each of (i), (ii), (iii) and (iv), a “Reporting Territory”);
(b) the amounts billed, invoiced and received by Company, its Affiliates and Sublicensees for each Product and Process, in each countryReporting Territory, and total ▇▇▇▇▇▇▇▇ or payments due or made for all Products and Processes;
(c) calculation of Net Sales for the applicable Reporting Period in each countryReporting Territory, including an itemized listing of permitted offsets and deductions;
(d) total royalties payable on Net Sales in U.S. dollars, together with the exchange rates used for conversion; and
(e) any other payments due to Hospital under this Agreement. If no amounts are due to Hospital for any Reporting Period, the report shall so state.
Appears in 2 contracts
Sources: Exclusive License Agreement (OvaScience, Inc.), Exclusive License Agreement (OvaScience, Inc.)
Sales Reports. Company shall report to Hospital the date of on which it achieves the First Commercial Sale in each country of the License Territory within [* * **] days of each such occurrence. Following the First Commercial Sale, Company shall deliver reports to Hospital within [* * **] days after the end of each Reporting Period. Each report under this Section 5.4 5.3 shall have substantially the format outlined in Appendix C, shall be certified as correct by an officer of Company and shall contain at least the following information as may be pertinent to a royalty accounting hereunder for the immediately preceding Reporting Period:
(a) the number of Products and Processes Sold by Company, its Affiliates and Sublicensees in each country;
(b) the amounts billed, invoiced and received by Company, its Affiliates and Sublicensees for each Product and Process, in each country, and total ▇▇▇▇▇▇▇▇ or payments due or made for all Products and Processes;
(c) calculation of Net Sales for the applicable Reporting Period in each country, including an itemized listing of permitted offsets and deductions;
(d) total royalties payable on Net Sales in U.S. dollars, together with the exchange rates used for conversion; and
(e) any other payments due to Hospital under this Agreement. If no amounts are due to Hospital for any Reporting Period, the report shall so state.
Appears in 2 contracts
Sources: Exclusive Patent License Agreement (Transcode Therapeutics, Inc.), Exclusive Patent License Agreement (Transcode Therapeutics, Inc.)
Sales Reports. Company shall report to Hospital the date of on which it achieves the First Commercial Sale in each country of the License Territory within [* * **] days of each such occurrence. Following the First Commercial Sale, Company shall deliver reports to Hospital within [* * **] days after the end of each Reporting Period. Each report under this Section 5.4 5.3 shall have substantially the format outlined in Appendix CB, shall be certified as correct by an officer of Company and shall contain at least the following information (or as otherwise determined by the Steering Committee) as may be pertinent to a royalty accounting hereunder for the immediately preceding Reporting Period:
(a) the number of Products and Processes Sold by Company, its Affiliates and Sublicensees in each countryof (i) the United States, (ii) the European Union, (iii) Japan and (iv) all other countries in aggregate (each of (i), (ii), (iii) and (iv), a “Reporting Territory”);
(b) the amounts billed, invoiced and received by Company, its Affiliates and Sublicensees for each Product and Process, in each countryReporting Territory, and total ▇▇▇▇▇▇▇▇ or payments due or made for all Products and Processes;
(c) calculation of Net Sales for the applicable Reporting Period in each countryReporting Territory, including an itemized listing of permitted offsets and deductions;
(d) total royalties payable on Net Sales in U.S. dollars, together with the exchange rates used for conversion; and
(e) any other payments due to Hospital under this Agreement. If no amounts are due to Hospital for any Reporting Period, the report shall so state.
Appears in 2 contracts
Sources: Exclusive License Agreement (OvaScience, Inc.), Exclusive License Agreement (OvaScience, Inc.)
Sales Reports. Company shall report to Hospital the date of the First Commercial Sale in each country of the License Territory within [* * *] thirty (30) days of each such occurrence. Following the First Commercial Sale, Company shall deliver reports to Hospital within [* * *] thirty (30) days after the end of each Reporting Period. Each report under this Section 5.4 shall have substantially the format outlined in Appendix C, shall be certified as correct by an officer of Company and shall contain at least the following information as may be pertinent to a royalty accounting hereunder for the immediately preceding Reporting Period:
(a) the number of Products and Processes Sold by Company, its Affiliates and Sublicensees in each country;
(b) the amounts billed, invoiced and received by Company, its Affiliates and Sublicensees for each Product and Process, in each country, and total ▇▇▇▇bill▇▇▇▇ or ▇▇ payments due or made for all Products and Processes;
(c) calculation of Net Sales for the applicable Reporting Period in each country, including an itemized listing of permitted offsets and deductions;
(d) total royalties payable on Net Sales in U.S. dollars, together with the exchange rates used for conversion; and
(e) any other payments due to Hospital under this Agreement. If no amounts are due to Hospital for any Reporting Period, the report shall so state. All sales reports shall be considered the Confidential Information of Company.
Appears in 2 contracts
Sources: Exclusive Patent License Agreement (ArcherDX, Inc.), Exclusive Patent License Agreement (ArcherDX, Inc.)
Sales Reports. Company shall report to Hospital the date of the First Commercial Sale in each country of the License Territory within [* * ***] days of each such occurrence. Following the First Commercial Sale, Company shall deliver reports to Hospital within [* * ***] days after the end of each Reporting Period. Each report under this Section 5.4 5.3 shall have substantially the format outlined in Appendix C, shall be certified as correct by an officer of Company and shall contain at least the following information as may be pertinent to a royalty accounting hereunder for the immediately preceding Reporting Period:
(a) the number of Licensed Products and Processes Sold by Company, its Affiliates and Sublicensees in each country;
(b) the amounts billed, invoiced and received by Company, its Affiliates and Sublicensees for each Product and ProcessLicensed Product, in each country, and total ▇▇▇▇▇▇▇▇ or payments due or made for all Products and ProcessesLicensed Products;
(c) calculation of Net Sales for the applicable Reporting Period in each country, including an itemized listing of permitted offsets and deductions;
(d) total royalties payable on Net Sales in U.S. dollars, together with the exchange rates used for conversion; and
(e) any other payments due to Hospital under this Agreement. If no amounts are due to Hospital for any Reporting Period, the report shall so state.
Appears in 2 contracts
Sources: Exclusive Patent License Agreement (Candel Therapeutics, Inc.), Exclusive Patent License Agreement (Candel Therapeutics, Inc.)
Sales Reports. Company shall report to Hospital the date of the First Commercial Sale in each country of the License Territory within [* * ***] days of each such occurrence. Following the First Commercial Sale, Company shall deliver reports to Hospital within [* * ***] days after the end of each Reporting Period. Each report under this Section 5.4 shall have substantially the format outlined in Appendix C, shall be certified as correct by an officer of Company and shall contain at least the following information as may be pertinent to a royalty accounting hereunder for the immediately preceding Reporting Period:
(a) the number of Products and Processes Sold by Company, its Affiliates and Sublicensees in each country;
(b) the amounts billed, invoiced and received by Company, its Affiliates and Sublicensees for each Product and Process, in each country, and total ▇▇▇▇▇▇▇▇ or payments due or made for all Products and Processes;
(c) calculation of Net Sales for the applicable Reporting Period in each country, including an itemized listing of permitted offsets and deductions;
(d) total royalties payable on Net Sales in U.S. dollars, together with the exchange rates used for conversion; and
(e) any other payments due to Hospital under this Agreement. If no amounts are due to Hospital for any Reporting Period, the report shall so state.
Appears in 2 contracts
Sources: Exclusive Patent License Agreement (Keros Therapeutics, Inc.), Exclusive Patent License Agreement (Keros Therapeutics, Inc.)
Sales Reports. Company shall report to Hospital the date of the First Commercial Sale in each country of the License Territory within [* * **] days of each such occurrence. Following the First Commercial Sale, Company shall deliver reports to Hospital within [* * **] days after the end of each Reporting Period. Each , a report under this Section 5.4 shall have substantially in the format outlined in Appendix C, which report shall be certified as correct by an officer of Company and shall contain at least the following information as may be pertinent to a royalty accounting hereunder for the immediately preceding Reporting Period:
(a) the number of Products and Processes Sold by Company, its Affiliates and Sublicensees in each country;
(b) the amounts billedbilled or invoiced, invoiced and received or if no ▇▇▇▇ or invoice, received, by Company, its Affiliates and Sublicensees for each category or class of Product and Process, in each country, and total ▇▇▇▇▇▇▇▇ or payments due or made for all Products and Processes;
(c) calculation of Net Sales for the applicable Reporting Period in each country, including an itemized listing of permitted offsets and deductionsdeductions (provided that in the case of sublicenses, this obligation shall apply only to the extent such itemized listing of permitted offsets and deductions is available from a Sublicensee under the terms of the relevant sublicense);
(d) total royalties payable on Net Sales in U.S. dollars, together with the exchange rates used for conversion; and
(e) any other payments due to Hospital under this Agreement. If no amounts are due to Hospital for any Reporting Period, the report shall so state.
Appears in 2 contracts
Sources: Exclusive Patent License Agreement (Editas Medicine, Inc.), Exclusive Patent License Agreement (Editas Medicine, Inc.)
Sales Reports. Company shall report to Hospital the date of the First Commercial Sale in each country of the License Territory within [* * *] Forty-five (45) days of each such occurrence. Following the First Commercial Sale, Company shall deliver reports to Hospital within [* * *] Forty-five (45) days after the end of each Reporting Period. Each report under this Section 5.4 shall have substantially the format outlined in Appendix C, shall be certified as correct by an officer of Company and shall contain at least the following information as may be pertinent to a royalty accounting hereunder for the immediately preceding Reporting Period:
(a) the number of Products and Processes Sold by Company, its Affiliates and Sublicensees in each country;
(b) the amounts billed, invoiced and received by Company, its Affiliates and Sublicensees for each Product and Process, in each country, and total ▇▇▇▇▇▇▇▇ or payments due or made for all Products and Processes;
(c) calculation of Net Sales for the applicable Reporting Period in each country, including an itemized listing of permitted offsets and deductions;
(d) total royalties payable on Net Sales in U.S. dollars, together with the exchange rates used for conversion; and
(e) any other payments due to Hospital under this Agreement. If no amounts are due to Hospital for any Reporting Period, the report shall so state.
Appears in 2 contracts
Sources: License Agreement (Fluoropharma Medical, Inc.), License Agreement (Fluoropharma Medical, Inc.)
Sales Reports. Company shall report to Hospital the date of on which it achieves the First Commercial Sale in each country of the License Territory within [* * *] thirty (30) days of each such occurrence. Following the First Commercial Sale, Company shall deliver reports to Hospital within [* * *] thirty (30) days after the end of each Reporting Period. Each report under this Section 5.4 5.3 shall have substantially the format outlined in Appendix CB, shall be certified as correct by an officer of Company and shall contain at least the following information as may be pertinent to a royalty accounting hereunder for the immediately preceding Reporting Period:
(a) the number of Products and Processes Sold by Company, its Affiliates and Sublicensees in each countrycountry of the License Territory;
(b) the amounts billed, invoiced and received by Company, its Affiliates and Sublicensees for each Product and Process, in each countrycountry of the License Territory, and total ▇▇▇▇▇▇▇▇ or payments due or made for all Products and Processes;
(c) calculation of Net Sales for the applicable Reporting Period in each countrycountry of the License Territory, including an itemized listing of permitted offsets and deductions;
(d) total royalties payable on Net Sales in U.S. dollars, together with the exchange rates used for conversion; and
(e) any other payments due to Hospital under this Agreement. If no amounts are due to Hospital for any Reporting Period, the report shall so state.
Appears in 2 contracts
Sources: Exclusive Patent License Agreement (ProQR Therapeutics B.V.), Exclusive Patent License Agreement (ProQR Therapeutics B.V.)
Sales Reports. Company shall report to Hospital the date of the First Commercial Sale in each country of the License Territory within [* * **] days of each such occurrence. Following the First Commercial Sale, Company shall deliver reports to Hospital Hospital, within [* * **] days after the end of each Reporting Period. Each , a report under this Section 5.4 shall have 5.3 substantially in the format outlined in Appendix C, which report shall be certified as correct by an officer of Company and shall contain at least the following information as may be pertinent to a royalty accounting hereunder for the immediately preceding Reporting Period:
(a) the number of Products and Processes Sold by Company, its Affiliates and Sublicensees in each country;
(b) the amounts billedbilled or invoiced, invoiced and received or if no ▇▇▇▇ or invoice, received, by Company, its Affiliates and Sublicensees for each category or class of Product and Process, in each country, and total ▇▇▇▇▇▇▇▇ or payments due or made for all Products and Processes;
(c) calculation of Net Sales for the applicable Reporting Period in each country, including an itemized listing of permitted offsets and deductionsdeductions (provided that in the case of sublicenses, this obligation shall apply only to the extent such itemized listing of permitted offsets and deductions is available from a Sublicensee under the terms of the relevant sublicense);
(d) total royalties payable on Net Sales in U.S. dollars, together with the exchange rates used for conversion; and
(e) any other payments due to Hospital under this Agreement. If no amounts are due to Hospital for any Reporting Period, the report shall so state.
Appears in 1 contract
Sources: Exclusive Patent License Agreement (Editas Medicine, Inc.)
Sales Reports. Company shall report to Hospital the date of on which it achieves the First Commercial Sale in each country of the License Territory within [* * *] thirty (30) days of each such occurrence. Following the First Commercial Sale, Company shall deliver reports to Hospital within [* * *] thirty (30) days after the end of each Reporting Period. Each report under this Section 5.4 5.3 shall have substantially the format outlined in Appendix CB, shall be certified as correct by an officer of Company and shall contain at least the following information as may be pertinent to a royalty accounting hereunder for the immediately preceding Reporting Period:
(a) the number of Products and Processes Sold by Company, its Affiliates and Sublicensees in each country;
(b) the amounts billed, invoiced and received by Company, its Affiliates and Sublicensees for each Product and Process, in each country, and total ▇▇▇▇▇▇▇▇ or payments due or made for all Products and Processes;
(c) calculation of Net Sales for the applicable Reporting Period in each country, including an itemized listing of permitted offsets and deductions;
(d) total royalties payable on Net Sales in U.S. dollars, together with the exchange rates used for conversion; and
(e) any other payments due to Hospital under this Agreement. If no amounts are due to Hospital for any Reporting Period, the report shall so state.
Appears in 1 contract
Sources: Exclusive Patent License Agreement (Tiziana Life Sciences PLC)
Sales Reports. Company shall report to Hospital the date of on which it achieves the First Commercial Sale in each country of the License Territory within [* * ***] days of each such occurrence. Following the First Commercial Sale, Company shall deliver reports to Hospital within [* * ***] days after the end of each Reporting Period. Each report under this Section 5.4 5.3 shall have substantially the format outlined in Appendix CE, shall be certified as correct by an officer of Company and shall contain at least the following information (or as otherwise determined by the Parties) as may be pertinent to a royalty accounting hereunder for the immediately preceding Reporting Period:
(a) the number of Products and Processes Sold by Company, its Affiliates and Sublicensees in each countryof (i) the United States, (ii) the European Union, (iii) Japan and (iv) all other countries in aggregate (each of (i), (ii), (iii) and (iv), a “Reporting Territory”);
(b) the amounts billed, billed or invoiced and received by Company, its Affiliates and Sublicensees for each Product and Process, in each countryReporting Territory, and total ▇▇▇▇▇▇▇▇ or payments due or made for all Products and Processes;
(c) calculation of Net Sales for the applicable Reporting Period in each countryReporting Territory, including an itemized listing of permitted offsets and deductions;
(d) total royalties payable on Net Sales in U.S. dollars, together with the exchange rates used for conversion; and
(e) any other payments due to Hospital under this Agreement. If no amounts are due to Hospital for any Reporting Period, the report shall so state.
Appears in 1 contract
Sources: Exclusive License Agreement
Sales Reports. Company shall report to Hospital the date of the First Commercial Sale in each country of the License Territory within [* * *] thirty (30) days of each such occurrence. Following the First Commercial Sale, Company shall deliver reports to Hospital within [* * *] thirty (30) days after the end of each Reporting Period. Each report under this Section 5.4 shall have substantially the format outlined in Appendix C, shall be certified as correct by an officer of Company and shall contain at least the following information as may be pertinent to a royalty accounting hereunder for the immediately preceding Reporting Period:
(a) the number of Products and Processes Sold by Company, its Affiliates and Sublicensees in each country;
(b) the amounts billed, invoiced and received by Company, its Affiliates and Sublicensees for each Product and Process, in each country, and total ▇b▇▇▇▇▇▇▇ or payments due or made for all Products and Processes;
(c) calculation of Net Sales for the applicable Reporting Period in each country, including an itemized listing of permitted offsets and deductions;
(d) total royalties payable on Net Sales in U.S. dollars, together with the exchange rates used for conversion; and
(e) any other payments due to Hospital under this Agreement. If no amounts are due to Hospital for any Reporting Period, the report shall so state.
Appears in 1 contract
Sources: Exclusive Patent License Agreement (Vicapsys Life Sciences, Inc.)
Sales Reports. Company shall report to Hospital the date of the First Commercial Sale in each country of the License Territory within [* * ***] days of each such occurrence. Following the First Commercial Sale, Company shall deliver reports to Hospital within [* * ***] days after the end of each Reporting Period. Each report under this Section 5.4 shall have substantially the format outlined in Appendix C, shall be certified as correct by an officer of Company and shall contain at least the following information as may be pertinent to a royalty accounting hereunder for the immediately preceding Reporting Period:
(a) the number of Products and Processes Sold by Company, its Affiliates and Sublicensees in each country;
(b) the amounts billed, invoiced and received by Company, its Affiliates and Sublicensees for each Product and Process, in each country, and total ▇b▇▇▇▇▇▇▇ or payments due or made for all Products and ProcessesProcesses ;
(c) calculation of Net Sales for the applicable Reporting Period in each country, including an itemized listing of permitted offsets and deductions;
(d) total royalties payable on Net Sales in U.S. dollars, together with the exchange rates used for conversion; and
(e) any other payments due to Hospital under this Agreement. If no amounts are due to Hospital for any Reporting Period, the report shall so state.
Appears in 1 contract
Sales Reports. Company shall report to Hospital the date of the First Commercial Sale in each country of the License Territory within [* * ***] days of each such occurrence. Following the First Commercial Sale, Company shall deliver reports to Hospital within [* * ***] days after the end of each Reporting Period. Each report under this Section 5.4 shall have substantially the format outlined in Appendix C, shall be certified as correct by an officer of Company and shall contain at least the following information as may be pertinent to a royalty accounting hereunder for the immediately preceding Reporting Period:
(a) the number of Products and Processes Sold by Company, its Affiliates Affiliates, Collaborators and Sublicensees in each country;
(b) the amounts billed, invoiced and received by Company, its Affiliates Affiliates, Collaborators and Sublicensees for each Product and Process, in each country, and total ▇▇▇▇▇▇▇▇ or payments due or made for all Products and Processes;
(c) calculation of Net Sales for the applicable Reporting Period in each country, including an itemized listing of permitted offsets and deductions;
(d) total royalties payable on Net Sales in U.S. dollars, together with the exchange rates used for conversion; and
(e) any other payments due to Hospital under this Agreement. If no amounts are due to Hospital for any Reporting Period, the report shall so state.
Appears in 1 contract
Sources: Exclusive Patent License Agreement (TScan Therapeutics, Inc.)